Regeneron Asks FDA To Authorize Its Antibody Treatment For COVID-19 For Emergency Use
- October 08, 2020
Bloomberg (10/8, Langreth) reports that “Regeneron Pharmaceuticals Inc. said it has asked federal regulators to authorize its antibody treatment for COVID-19 for emergency use.” The company recently “reported preliminary results from a trial showing that the cocktail could reduce virus levels in coronavirus patients outside of the hospital.”
The New York Times (10/7, Thomas) reports that Regeneron “said that at first, access to the treatment would be extremely limited, with only enough doses for 50,000 patients.”